Hobikoglu Gultekin F, Norgaz Tugrul, Aksu Huseyin, Ozer Orhan, Erturk Mehmet, Destegul Evren, Akyuz Umit, Unal Dai Sennur, Narin Ahmet
Siyami Ersek Thorax and Cardiovascular Surgery Center, Department of Cardiology, Istanbul, Turkey.
Can J Cardiol. 2007 Mar 1;23(3):201-6. doi: 10.1016/s0828-282x(07)70744-4.
The relationships between clinical events and acetylsalicylic acid resistance (AR), as well as its frequency, have been established in stable patients with coronary artery disease (CAD). Although acute coronary syndrome (ACS) patients taking acetylsalicylic acid have been accepted as a high-risk population, the role of AR has not been investigated in these patient groups. Thus, in the present study, the impact of AR was investigated in patients with ACS who were taking acetylsalicylic acid.
Between January 2001 and February 2003, 140 ACS patients were included in the present prospective study. All patients had ACS while taking acetylsalicylic acid. Coronary angiographic scores for severity and extent of CAD were determined for all patients. The effect of acetylsalicylic acid on platelet function was assessed by the platelet function analyzer PFA-100 (Dade Behring, USA). The primary end point was the composite of death, myocardial infarction, cerebrovascular accident and revascularization. The mean follow-up period was 20 months.
Patients with AR were older than patients without AR (63.8+/-10.8 years versus 58.3+/-11.2 years; P=0.005). Moreover, myocardial damage was higher in patients with AR according to cardiac troponin T values (1.11+/-1.3 mug/L versus 0.41+/-0.5 mug/L; P=0.01). The composite end point of death, myocardial infarction, cerebrovascular accident or revascularization was present in 16 of 45 patients (35%) with AR and in 13 of 79 patients (16%) without AR (hazard ratio 2.46, 95% CI 1.18 to 5.13; P=0.016). After adjustment for age, platelet count, cardiac troponin T value and CAD severity score, AR remained an independent predictor for long-term adverse events (hazard ratio 3.03, 95% CI 1.06 to 8.62; P=0.038).
The clinical event rate was found to be higher in ACS patients with AR than in those without AR. Thus, it may be concluded that there is a strong correlation between a worse prognosis and AR in these patients.
在稳定型冠心病(CAD)患者中,已确立临床事件与阿司匹林抵抗(AR)之间的关系及其发生率。尽管服用阿司匹林的急性冠脉综合征(ACS)患者被视为高危人群,但AR在这些患者群体中的作用尚未得到研究。因此,在本研究中,对服用阿司匹林的ACS患者中AR的影响进行了调查。
在2001年1月至2003年2月期间,140例ACS患者被纳入本前瞻性研究。所有患者在服用阿司匹林时发生ACS。为所有患者确定CAD严重程度和范围的冠状动脉造影评分。通过血小板功能分析仪PFA - 100(美国达德拜灵公司)评估阿司匹林对血小板功能的影响。主要终点是死亡、心肌梗死、脑血管意外和血运重建的复合终点。平均随访期为20个月。
AR患者比无AR患者年龄更大(63.8±10.8岁对58.3±11.2岁;P = 0.005)。此外,根据心肌肌钙蛋白T值,AR患者的心肌损伤更高(1.11±1.3μg/L对0.41±0.5μg/L;P = 0.01)。45例AR患者中有16例(35%)出现死亡、心肌梗死、脑血管意外或血运重建的复合终点,79例无AR患者中有13例(16%)出现该复合终点(风险比2.46,95%可信区间1.18至5.13;P = 0.016)。在调整年龄、血小板计数、心肌肌钙蛋白T值和CAD严重程度评分后,AR仍然是长期不良事件的独立预测因素(风险比3.03,95%可信区间1.06至8.62;P = 0.038)。
发现有AR的ACS患者的临床事件发生率高于无AR的患者。因此,可以得出结论,在这些患者中,预后较差与AR之间存在很强的相关性。